Alle Studien
RekrutierungTherapeutische Bestätigung (Phase III)Interventionell

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

This research study is for people in the UK who have follicular lymphoma, which is a type of blood cancer that affects certain white blood cells. This study is testing a new drug called Ibrutinib. Researchers want to see if combining Ibrutinib with another standard drug, Rituximab, is more effective than just Rituximab alone. Participants will be randomly assigned to one of two groups: one group will receive Ibrutinib plus Rituximab, and the other will receive a dummy drug (placebo) plus Rituximab. The main goal is to find out if the Ibrutinib combination helps people live longer without their cancer getting worse, and to understand any side effects. This is a crucial step in finding better treatments for follicular lymphoma.

Auf einen Blick

Status
Rekrutierung
Phase
Therapeutische Bestätigung (Phase III)
Sponsor
AbbVie Deutschland GmbH & Co. KG
Einschreibeziel
231
Starten
19 Feb 2024

Worum geht es in dieser Studie?

This research study, called a clinical trial, is looking for a better way to treat follicular lymphoma. This is a type of cancer that starts in certain white blood cells called lymphocytes. When you're first diagnosed with follicular lymphoma and haven't had treatment before, doctors look for the best treatment to help you.

In this study, they are investigating a new drug called Ibrutinib. This drug works by targeting a specific protein in the cancer cells. The researchers want to see if adding Ibrutinib to a standard treatment, Rituximab, is more effective than the standard treatment alone. Rituximab is a common treatment for follicular lymphoma that helps your immune system fight the cancer cells.

The main aim is to find out if people who receive Ibrutinib along with Rituximab live longer without their cancer growing or getting worse. This is an important measure because it tells us how well the treatment is controlling the cancer. The study will also carefully check for any side effects and how people feel overall. By understanding these results, doctors can make better decisions about future treatments for follicular lymphoma.

Wichtige Erkenntnisse

  • This study is for people with newly diagnosed follicular lymphoma.
  • It's comparing a new drug (Ibrutinib) with a standard treatment (Rituximab).
  • The main goal is to see if Ibrutinib helps people live longer without their cancer worsening.
  • Participants will be randomly assigned to one of two treatment groups.
  • All study visits and treatments will be provided by the research team.
  • Sie können die Teilnahme jederzeit beenden, wenn Sie möchten.

Wer könnte berechtigt sein?

This study is looking for adults who are at least 18 years old. Both men and women can take part.

To be eligible, you must have been recently diagnosed with follicular lymphoma and have not yet received any treatment for it. This is important because the study wants to see how the new treatment works in people who are just starting their cancer journey.

There will be other detailed health checks to make sure the study is safe and suitable for you. These will be discussed with you by the study doctor or nurse to see if you meet all the requirements.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Have you been diagnosed with follicular lymphoma?
  3. Have you NOT received any treatment for your follicular lymphoma yet?
  4. Are you able to take capsules by mouth?
  5. Are you willing to attend regular hospital or clinic visits?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part in this study, you will be randomly placed into one of two groups. Neither you nor your doctor will know which group you are in. One group will receive the new drug Ibrutinib along with Rituximab, and the other group will receive a dummy pill (placebo) along with Rituximab. The Ibrutinib or placebo is a capsule you take by mouth.

You will have regular visits to the hospital or clinic for treatments, check-ups, and to monitor how you are doing. These visits will involve blood tests, physical examinations, and possibly scans to see how your cancer is responding and to check for any side effects. The study also looks at how long the treatment keeps the cancer under control.

The exact length of your participation will depend on how you respond to the treatment and the study's design. The study team will explain the full schedule of visits and assessments to you before you agree to take part.

Potenzielle Risiken und Vorteile

Taking part in a clinical trial might offer potential benefits, such as access to a new treatment (Ibrutinib) before it's widely available. The treatment might be more effective at controlling your follicular lymphoma than standard care. However, there are also potential risks, including side effects from the study drugs. These side effects can vary from mild to severe, and the study team will monitor you closely for them. You will be given detailed information about known side effects before you decide to join. It is very important to remember that participating in any clinical trial is always voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.

Standorte (11)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Italien
  • —
    Unbestätigt
    Griechenland
  • —
    Unbestätigt
    Österreich
  • —
    Unbestätigt
    Niederlande
  • —
    Unbestätigt
    Ungarn
  • —
    Unbestätigt
    Tschechien
  • —
    Unbestätigt
    Polen
  • —
    Unbestätigt
    Belgien
  • —
    Unbestätigt
    Spanien
  • —
    Unbestätigt
    Portugal
  • —
    Unbestätigt
    Frankreich

Häufige Fragen

What is Ibrutinib?

Ibrutinib is a new drug being tested that aims to block a specific protein involved in the growth of follicular lymphoma cells.

Was ist ein 'Placebo'?

A placebo is a dummy pill that looks exactly like the study drug but contains no active medicine. It helps researchers compare the effects of the active drug.

Werde ich wissen, welche Behandlung ich bekomme?

No, this is a 'double-blind' study, meaning neither you nor your doctors will know if you're getting Ibrutinib or the placebo. This helps ensure fair and unbiased results.

What does 'progression-free survival' mean?

It's a way for doctors to measure how long people live without their cancer getting worse or growing. It helps measure how effective a treatment is at controlling the cancer.

Kann ich die Studie verlassen, wenn ich meine Meinung ändere?

Yes, absolutely. Your participation is completely voluntary, and you can withdraw from the study at any time without having to give a reason.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Multicenter, Randomized, Double-blind, Placebo-controlled … wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.